Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
NRXPthis companyNRx Pharmaceuticals, Inc.	$2.42	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
CUECue Biopharma, Inc.	$19.50	-1.09×	1.09×	1.05×	-0.24×	-850.1%	100.0%	-96.6%	-96.9%	-100.6%	-86.6%	-75.6%	0.16×	0.93×	-74.29×	2.74×	0.0%	2	-30.14	1	D+
EQEquillium, Inc.	$1.59	-3.97×	4.98×	0×	-5.06×	-77.1%	0.0%	0.0%	0.0%	-78.3%	-83.3%	-16.0%	0.03×	1.33×	0×	10.32×	0.0%	1	14.51	2	C
HOWLWerewolf Therapeutics, Inc.	$1.05	-0.48×	1.18×	0×	0.36×	-2.6%	0.0%	0.0%	0.0%	-245.2%	-173.4%	-206.8%	0.38×	0.9×	-11.5×	1.62×	0.0%	4	-26.12	2	C+
IPSCCentury Therapeutics, Inc.	$1.74	-9.04×	0.54×	0.79×	19.64×	85.0%	88.0%	-13.8%	-8.8%	-6.0%	-7.2%	-121.6%	0.27×	-5.3×	0×	5.97×	0.0%	1	-1.94	2	C
KPTIKaryopharm Therapeutics Inc.	$0.04	-0.41×	-0.27×	0.55×	-1.69×	-58773.0%	95.9%	-62.1%	-134.2%	66.9%	-236.6%	-93.6%	-0.8×	-1.15×	-1.98×	1.12×	0.0%	2	-27.45	2	B-
Peer median	—	-1.09×	1.09×	0.55×	-0.24×	-77.1%	88.0%	-13.8%	-8.8%	-78.3%	-86.6%	-93.6%	0.16×	0.9×	-1.98×	2.74×	0.0%	2	-26.12	2	—